Impaired DNase1-mediated degradation of neutrophil extracellular traps is associated with acute thrombotic microangiopathies.

BACKGROUND: Acute thrombotic microangiopathies (TMAs) are characterized by excessive microvascular thrombosis and are associated with markers of neutrophil extracellular traps (NETs) in plasma. NETs are composed of DNA fibers and promote thrombus formation through the activation of platelets and clotting factors. OBJECTIVE: The efficient removal of NETs may be required to prevent excessive thrombosis such as in TMAs. To test this hypothesis, we investigated whether TMAs are associated with a defect in the degradation of NETs. METHODS AND RESULTS: We show that NETs generated in vitro were efficiently degraded by plasma from healthy donors. However, NETs remained stable after exposure to plasma from TMA patients. The inability to degrade NETs was linked to a reduced DNase activity in TMA plasma. Plasma DNase1 was required for efficient NET degradation and TMA plasma showed decreased levels of this enzyme. Supplementation of TMA plasma with recombinant human DNase1 restored NET-degradation activity. CONCLUSIONS: Our data indicate that DNase1-mediated degradation of NETs is impaired in patients with TMAs. The role of plasma DNases in thrombosis is, as of yet, poorly understood. Reduced plasma DNase1 activity may cause the persistence of pro-thrombotic NETs and thus promote microvascular thrombosis in TMA patients.

Histopathology of lupus-like nephritis in Dnase1-deficient mice in comparison to NZB/W F1 mice.

Deoxyribonuclease 1 (Dnase1)-deficient mice develop symptoms of Systemic lupus erythematosus (SLE). Here we analysed the renal histopathology of these animals in comparison to F1 hybrids of New Zealand black and white mice (NZB/W F1), an established model of SLE. Animals were divided into three groups according to the presence of anti-nuclear antibodies (ANA) and renal lesions. Groups 1a-1c were healthy, whereas group 2 and 3 were classified as lupus-prone and affected. Subendothelial and/or mesangial immune complex deposits, mesangial and endocapillary proliferation, haematoxylin bodies and platelet aggregation were detected in both mouse strains but were more severe in the NZB/W F1 mice. The lupus nephritis was classified as a proliferating (WHO type III or IV), which appeared to be preceded by a mesangial form (WHO type II). Subclassification of the ANA revealed a high prevalence of anti-nucleosome antibodies in Dnase1-deficient mice, whereas NZB/W F1 mice developed autoantibodies against a broad range of chromatin constituents. Mapping of the murine Dnase1 gene locus to chromosome 16A1-3 did not coincide with one of the reported susceptibility loci in the NZB/W F1 model, although a reduced Dnasel serum and urine activity has been described previously in these mice.

Features of systemic lupus erythematosus in Dnase1-deficient mice.

Systemic lupus erythematosus (SLE) is a multifactorial autoimmune disease that affects over one million people in the United States. SLE is characterized by the presence of anti-nuclear antibodies (ANA) directed against naked DNA and entire nucleosomes. It is thought that the resulting immune complexes accumulate in vessel walls, glomeruli and joints and cause a hypersensitivity reaction type III, which manifests as glomerulonephritis, arthritis and general vasculitis. The aetiology of SLE is unknown, but several studies suggest that increased liberation or disturbed clearance of nuclear DNA-protein complexes after cell death may initiate and propagate the disease. Consequently, Dnase1, which is the major nuclease present in serum, urine and secreta, may be responsible for the removal of DNA from nuclear antigens at sites of high cell turnover and thus for the prevention of SLE (refs 7-11). To test this hypothesis, we have generated Dnase1-deficient mice by gene targeting. We report here that these animals show the classical symptoms of SLE, namely the presence of ANA, the deposition of immune complexes in glomeruli and full-blown glomerulonephritis in a Dnase1-dose-dependent manner. Moreover, in agreement with earlier reports, we found Dnase1 activities in serum to be lower in SLE patients than in normal subjects. Our findings suggest that lack or reduction of Dnase1 is a critical factor in the initiation of human SLE.

Cell-type specific activation of the polyomavirus F9-1 regulatory region in transgenic mice.

To characterize the activity of the polyomavirus regulatory region, two hybrid marker genes were constructed. In the first construct, the early promoter regulates expression of the CAT gene and the late promoter regulates expression of the lacZ gene. In the second construct, the lacZ gene was placed under the control of the early promoter. The fusion constructs were introduced into the mouse germline. Gene expression was analysed in the generated transgenic mice. A pronounced cell-type specific activation of the transcriptional control region was found in different tissues of the developing embryo and in the adult animal. The control region is recognized and activated in early preimplantation embryos. Around the time of implantation, sequential activation of the Py regulatory region was first observed in differentiating cells. Stage- and tissue-specific expression were noted later in embryonic development. Comparing reporter gene expression on the single-cell level, the different viral promoters display identical expression patterns throughout ontogenesis. Quantitative analysis revealed that marker gene expression from the late promoter was significantly higher than from the early promoter. Furthermore, the cell-type specificity of the control region is not altered in the presence of its regulatory protein, the LT.